{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:15:49Z","timestamp":1791000949154,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602406"],"award-info":[{"award-number":["81602406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572612"],"award-info":[{"award-number":["81572612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>RIG\u2010I is associated with the occurrence and development of many tumors. However, the role of RIG\u2010I in radiotherapy and chemotherapy in NPC has not been reported to date. In our study, RIG\u2010I expression was significantly reduced in chemoradiotherapy\u2010resistant NPC tissues and cells compared with that in therapy\u2010sensitive tissues and cells. RIG\u2010I expression increased in nonresistant NPC cells, including CNE1 and CNE2, in a dose\u2010dependent manner with increasing chemotherapy drug concentration or radiotherapy dose. RIG\u2010I overexpression promoted radiotherapy and chemotherapy sensitivity in NPC cells, leading to cellular apoptosis and increased expression of the proapoptotic factors BAX and caspase\u20103. Similarly, RIG\u2010I knockdown in NPC cells promoted chemoradiotherapy resistance and reduced apoptosis. Analysis of microarray data indicated that the expression of IFN\/JAK2 and endoplasmic reticulum (ER) stress response markers, such as JAK2, STAT1, IRF9, IFNB1, IRF3, p\u2010IRF3, XBP1, ATF6, IFIT2, and ISG15, was inhibited in chemoradiotherapy\u2010resistant cells compared with that in sensitive cells. Conversely, activation of IFN\/JAK2 and ER stress response pathways in NPC cells reduced paclitaxel resistance and increased apoptosis. RIG\u2010I promotes IFN\/JAK2 and ER stress response\u2010mediated apoptosis to inhibit chemoradiation resistance in nasopharyngeal carcinoma.<\/jats:p>","DOI":"10.1002\/cam4.2501","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T06:45:31Z","timestamp":1567061131000},"page":"6344-6357","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["RIG\u2010I promotes IFN\/JAK2 expression and the endoplasmic reticulum stress response to inhibit chemoradiation resistance in nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"8","author":[{"given":"Di","family":"Jing","sequence":"first","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Teaching and Research Section of Surgery Xiangnan University Affiliated Hospital Chenzhou Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang\u2010Ti","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oncology The First People's Hospital of YueYang Yue Yang Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology The First People's Hospital of YueYang Yue Yang Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-7531","authenticated-orcid":false,"given":"Liang\u2010Fang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun\u2010Quan","family":"Sun","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12989"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00055-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.03.054"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.010.10377"},{"issue":"8","key":"e_1_2_8_6_1","first-page":"381","article-title":"Nasopharyngeal carcinoma incidence and mortality in China in 2010","volume":"33","author":"Wei KR","year":"2014","journal-title":"Chin J Cancer"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2237"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2016.03.03"},{"issue":"11","key":"e_1_2_8_9_1","first-page":"912","article-title":"FDA approves treatment IND protocol for taxol","volume":"11","year":"1992","journal-title":"Clin Pharm"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.21451"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19690"},{"issue":"9","key":"e_1_2_8_12_1","first-page":"1059","article-title":"Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non\u2010small\u2010cell lung cancer","volume":"83","author":"Ratanatharathorn V","year":"2000","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2893-6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.53"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065061"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20804"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-009-1112-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00822-X"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2015.0056"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.54"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2014.10.004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283363980"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2014.1001287"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.11.4.19228"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-010-0952-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/jb.170.7.2939-2946.1988"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00142"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0050-x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.04.008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.067"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2015.10.015"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.126"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2013.55"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00176"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0023"},{"issue":"5","key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18632\/genesandcancer.111","article-title":"Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug\u2010resistant chronic myelogenous leukemia","volume":"7","author":"Chakraborty SN","year":"2016","journal-title":"Genes Cancer"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000550"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484622"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2016.05.005"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2016.12.001"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11028"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.83"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.26"},{"issue":"3","key":"e_1_2_8_44_1","first-page":"643","article-title":"Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy\u2010lysosome and ER stress","volume":"38","author":"Kawaguchi T","year":"2011","journal-title":"Int J Oncol"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17678"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1684"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1210\/mend.15.9.0699"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2501","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:05:54Z","timestamp":1694192754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":46,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1002\/cam4.2501"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2501","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"2019-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}